论文部分内容阅读
糖尿病肾病（DKD）是糖尿病最常见的慢性并发症，是终末期肾脏病（ESRD）的主要病因。DKD的预警、早期诊断和评估疾病进展对于改善预后至关重要。估算肾小球滤过率（eGFR）和尿白蛋白排泄率（AER）是DKD的主要诊断依据，但灵敏度和特异度存在不足。近年来，DKD新型生物标志物的价值逐渐受到重视。本文对近年来DKD新型生物标志物的临床研究进行评述，为DKD临床诊断和预后评估提供参考。“,”Diabetic kidney disease (DKD) is the most common chronic complication of diabetes mellitus and the major cause of end stage renal disease (ESRD). Prediction, early diagnosis and evaluation of disease progression are crucial to improve the prognosis of DKD. Estimated glomerular filtration rate (GFR) and urinary albumin excretion rate (AER) are the main diagnostic biomarkers of DKD. However, the sensitivity and specificity are insufficient. In recent years, more and more attention has been paid to the value of novel biomarkers of DKD. This article reviews the clinical studies of novel biomarkers of DKD, in order to provide reference for clinical diagnosis and prognosis evaluation of DKD.